Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study - Reuters

reuters.com - (Reuters) - About 40% of patients who received a combination of Bristol-Myers Squibb Co’s immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer (NSCL…